Hematologics, Inc.

2024 Publication List – Articles, Posters, Presentations, & Abstracts

Bhagwat, A.S., Torres, L., Shestova, O. *et al.* Cytokine-mediated CAR T therapy resistance in AML. *Nat Med* **30**, 3697–3708 (2024). https://doi.org/10.1038/s41591-024-03271-5

DiPersio, J.F., Koehne, G., Shah, N.N., Bernard, L., Suh, H.C., Koura, D., Perales, M.A., Tamari, R., Mushtaq, M.U., Maakaron, J.E. and Loken, M.R., 2024. A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML). *Blood*, *144*, p.2873.

Shastri, V.M., Marchi, F., Loken, M.R. and Lamba, J.K., 2024. Identification of Interstitial Loss of Heterozygosity (LOH) Regions Flanking CD33 Locus in AML Patients. *Blood*, *144*, p.1543.

Le, Q., Hadland, B., Smith, J.L., Leonti, A., Huang, B.J., Ries, R., Hylkema, T.A., Castro, S., Tang, T.T., McKay, C.N. and Perkins, L., 2024. CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target. The Journal of Clinical Investigation, 134(16).

Lira, I., Kirkey, D.C., Nicolaidou, M., Muller, H., Barisa, M., Blankenfeld, M., Hawkins, G., McKay, C., Root, C., Pardo, L. and Loken, M.R., 2024. Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia. *Blood*, *144*, p.4793.

Lira, I., Kirkey, D.C., Nicolaidou, M., Muller, H., Barisa, M., Blankenfeld, M., Hawkins, G., McKay, C., Root, C., Pardo, L. and Loken, M.R., 2024. Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia. *Blood*, *144*, p.4793.

Hawkins, G., Kirkey, D., Panahi, N., Blankenfeld, M., Lira, I., Hylkema, T., McKay, C., Root, C., Peplinski, J.H., Wallace, L.K. and Ries, R.E., 2024. Discovery and Immunotherapeutic Targeting of the Tumor-Specific Target LAMP5 in Acute Myeloid Leukemia. *Blood*, *144*, p.3413.

Jacoby, M.A., Duncavage, E.D., Khanna, A. et al. Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response. Leukemia (2024). https://doi.org/10.1038/s41375-024-02426-0

Loken, M.R. and Hudson, C.A., 2024. Measuring response to therapy in AML: Difference from normal flow cytometry vs RQ-PCR. *Methods in Cell Biology*, *186*, pp.233-247.

Srivatsan, S.N., Chavez, M., Miller, C., Menssen, A., Khanna, A., Fronick, C., Fulton, R., Heath, S., Logothetis, C., Burton, T. and Donaldson, V., 2024. 8. Reduced subclone diversity in clonal cytopenia of undetermined significance compared to myelodysplastic syndrome. *Cancer Genetics*, *286*, p.S3.

3161 Elliott Avenue, Suite 200
Seattle, Washington 98121
Phone (800) 860-0934 or (206) 223-2700 Fax (206) 223-5550

Menssen AJ, Hudson CA, Alonzo T, Gerbing R, Pardo L, Leonti A, Cook JA, Hsu FC, Lott LL, Dai F, Fearing C, Ghirardelli K, Hylkema T, Tarlock K, Loeb KR, Kolb EA, Cooper T, Pollard J, Wells DA, Loken MR, Aplenc R, Meshinchi S, Brodersen LE. CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group. Haematologica. 2024 Oct 1;109(10):3182-3193. doi: 10.3324/haematol.2023.283757. PMID: 38299667; PMCID: PMC11443400.

Cook, J.A., Lott, L., Perry, J., Eckel, A.M., Xu, D., Hudson, C.A., Wells, D.A., Loken, M.R. and Menssen, A.J., 2024. Fusion Harboring Mast Cells Can Explain Molecular Positivity in Flow Cytometric MRD Negative Core Binding Factor AML. *Blood Journal*, pp.blood-2024024264.

Hitzler, J.K., Alonzo, T.A., Gerbing, R., Wang, J., Beckman, A., Hirsch, B., Raimondi, S.C., Chisholm, K.M., Viola, S.A., Verma, A. and Brodersen, L.E., 2024. Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group. *Blood*, *144*, p.2949.

Pollard, J.A., Alonzo, T.A., Gerbing, R., Kutny, M.A., Hirsch, B., Raca, G., Leger, K., Wilkes, J.J., Wadhwa, A., Graff, Z. and Pabari, R., 2024. A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO-a Report from the Children's Oncology Group. *Blood*, *144*, p.967.

Stevens, A.M., Terrell, M., Rashid, R., Fisher, K.E., Marcogliese, A.N., Gaikwad, A., Rao, P., Vrana, C., Krueger, M., Loken, M. and Menssen, A.J., 2024. Addressing a Pre-Clinical Pipeline Gap: Development of the Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Program at Texas Children's Hospital at Baylor College of Medicine. *Biomedicines*, *12*(2), p.394.

Hartmann, L., Cook, J., Lott, L., Perry, J., Wells, D., Loken, M., Menssen, A. and Xu, D., 2024. 18. Tumor specific cell sorting improves sensitivity of FISH: Implications for patients with hematologic malignancies. *Cancer Genetics*, *286*, p.S6. ***Poster presentation at CGC 2024 Annual Meeting (LH)***

Amenech Ashango, Nigar Zaidi, Chad Hudson MD PhD, Denise Wells MD, William Palko MD, Ashley Eckel MD PhD. Myeloid neoplasm with *RUNX1* mutation demonstrating an associated plasmacytoid dendritic cell proliferation. International Clinical Cytometry Society (ICCS) 2024. ***Oral presentation at 2024 ICCS Meeting (AE)***

Eckel A, Olson N, Hartmann L, Cheng H, Xu D. Patient with blast phase multilineage (B and myeloid) neoplasm with *FGFR1* rearrangement and *RUNX1* mutation. European Association for Haematopathology (EAHP) 2024.

Windisch, R., Soliman, S., Hoffmann, A., Chen-Wichmann, L., Danese, A., Vosberg, S., Bravo, J., Lutz, S., Kellner, C., Fischer, A., Gebhard, C., Redondo Monte, E., Hartmann, L., Schneider, S., Beier, F., Strobl, C. D., Weigert, O., Peipp, M., Schündeln, M., Stricker, S. H., … Wichmann, C. (2024). Engineering an inducible leukemia-associated fusion protein enables large-scale ex vivo production of functional human phagocytes. *Proceedings of the National Academy of Sciences of the United States of America*, *121*(25), e2312499121. https://doi.org/10.1073/pnas.2312499121

Curtis A Lachowiez, Joshua F Zeidner, Ashley M. Eckel, Daniel T Peters, Jacob Fang, Amenech Ashango, Andy Kaempf, Fangyan Dai, Christopher A. Eide, Stephen E. Kurtz, Theodore P Braun, Ronan T. Swords, Jennifer N. Saultz, Jeffrey W. Tyner, Daniel A Pollyea, Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML, Blood, Volume 144, Supplement 1, 2024, Page 62.

Patents

System, method, and article for detecting abnormal cells using multi-dimensional analysis; MR Loken, SN Joshi
US Patent 12,046,331
2024

System, method, and article for detecting abnormal cells using multi-dimensional analysis; MR Loken, AP Voigt
US Patent App. 18/186,747
2024

3161 Elliott Avenue, Suite 200
Seattle, Washington 98121
Phone (800) 860-0934 or (206) 223-2700 Fax (206) 223-5550